Skip to main content
SpringerLink
Log in

Treatment Approaches for Alzheimer’s Disease

  • Chapter
Molecular Mechanisms of Neurodegenerative Diseases

Part of the book series: Contemporary Clinical Neuroscience ((CCNE))

  • 168 Accesses

Abstract

Alzheimer’s disease (AD) is the most common cause of dementia and can be thought of as a prototype of a primary neurodegenerative disorder (1,2). Studies of the epidemiology of AD have demonstrated an age-related increase in prevalence from approximately 10% in persons 65 yr old to as high as 50% in persons reaching 85 yr of age (3). In addition to age, family history, head trauma, general anesthesia, and a poor education have been implicated as risk factors for AD (4–6). The “graying” of our society as well as successes in developing treatments for other chronic disorders implies that unless ways are found to reduce the incidence of AD, the societal costs attributable to AD will increase in the coming years. The public health problem posed by AD is succintly illustrated by the fact that the current annual cost associated with AD in the United States is approximately US $100 billion. The projected quadupling of the affected population in the next 20–30 yr (7) serves to underscore the scope of the challenge.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Treves, T. A. (1991) Epidemiology of Alzheimer’s disease. Psychiatr. Clin. North Am. 14, 251–265.

    PubMed  CAS  Google Scholar 

  2. Fratiglioni, L. (1996) Epidemiology of Alzheimer’s disease and current possibilities for prevention. Acta Neurol. Scand. 165 (Suppl.), 33–40.

    Article  CAS  Google Scholar 

  3. Fratiglioni, L., Forsell, Y., Aguero, T. H., and Winblad, B. (1994) Severity of dementia and institutionalization in the elderly, prevalence data from an urban area in Sweden. Neuroepidemiology 13, 79–88.

    Article  PubMed  CAS  Google Scholar 

  4. Bachman, D. L., Wolf, P. A., Linn, R., Knoefel, J. E., Cobb, J., Belanger, A., et al. (1992) Prevalence of dementia and probable senile dementia of the Alzheimer type in the Framingham Study. Neurology 42, 115–119.

    Article  PubMed  CAS  Google Scholar 

  5. Hendrie, H. C. (1997) Epidemiology of Alzheimer’s disease. Geriatrics 52 (Suppl. 2), S4 - S8

    PubMed  Google Scholar 

  6. Slooter, A. J. and van Duijn, C. M. (1997) Genetic epidemiology of Alzheimer disease. Epidemiol. Rev. 19, 107–119.

    Article  PubMed  CAS  Google Scholar 

  7. Whitehouse, P. J. (1997) Pharmacoeconomics of dementia. Alzheimer Dis. Associat. Dis. 11 (Suppl 5), S22 - S32.

    Google Scholar 

  8. Brookmeye, R., Gray, S., and Kawas, C. (1998) Projections of Alzheimer’s disease in the United States and the public health impact of delaying disease onset. Am. J. Public Health 88, 1337–1342.

    Article  Google Scholar 

  9. Morris, J. C. (1997) Alzheimer’s disease, a review of clinical assessment and management issues. Geriatrics 52 (Suppl. 2), S22 - S25

    PubMed  Google Scholar 

  10. Hansen, L. A. (1997) The Lewy body variant of Alzheimer disease. J. Neural Transm. 51 (Suppl.), 83–93.

    Article  CAS  Google Scholar 

  11. Johnson, J. K., Head, E., Kim, R., Starr, A., and Cotman, C. W. (1999) Clinical and pathological evidence for a frontal variant of Alzheimer disease. Arch. Neurol. 56, 1233–1239.

    Article  PubMed  CAS  Google Scholar 

  12. Brooks, J. O. and Yesavage, J. A. Identification of fast and slow decliners in Alzheimer disease, a different approach. Alzheimer Dis. Associat. Dis. 9(Suppl. 1), S 19-S25

    Google Scholar 

  13. Piccini, C., Bracco, L., Falcini, M., Pracucci, G., and Amaducci, L. (1995) Natural history of Alzheimer’s disease, prognostic value of plateaux. J. Neurol. Sci. 131, 177–182.

    Article  PubMed  CAS  Google Scholar 

  14. Rasmusson, D. X., Brandt, J., Steele, C., Hedreen, J. C., Troncoso, J. C., and Folstein, M. F. (1996) Accuracy of clinical diagnosis of Alzheimer disease and clinical features of patients with non-Alzheimer disease neuropathology. Alzheimer Dis. Associat. Disord. 10, 180–188.

    Article  CAS  Google Scholar 

  15. McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., and Stadlan, E. M. (1984) Clinical diagnosis of Alzheimer’s disease, report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’ s Disease. Neurology 34, 939–944.

    Article  PubMed  CAS  Google Scholar 

  16. Galasko, D., Hansen, L. A., Katzman, R., Wiederholt, W., Masliah, E., Terry, R., et al. (1994) Clinical-neuropathological correlations in Alzheimer’s disease and related dementias. Arch. Neurol. 51, 888–895.

    Article  PubMed  CAS  Google Scholar 

  17. Filley, C. M., Chapman, M. M., and Dubovsky, S. L. (1996) Ethical concerns in the use of palliative drug treatment for Alzheimer’s Disease. J. Neuropsychiatry Clin. Neurosci. 8, 202–205.

    PubMed  CAS  Google Scholar 

  18. McLendon, B. M. and Doraiswamy, P. M. (1999) Defining meaningful change in Alzheimer’s disease trials, the donepezil experience. J. Geriatr. Psychiatry Neurol. 12, 39–48.

    Article  PubMed  CAS  Google Scholar 

  19. Domingo, J. L. (1995) Adverse effects of potential agents for the treatment of Alzheimer’s disease, a review. Adverse Drug Reacti. Toxicol. Rev. 14, 101–115.

    CAS  Google Scholar 

  20. Fenn, P. and Gray, A. (1999) Estimating long-term cost savings from treatment of Alzheimer’s disease. A modelling approach. Pharmacoeconomics 16, 165–174.

    Article  PubMed  CAS  Google Scholar 

  21. Neumann, P. J., Hermann, R. C., Kuntz, K. M., Araki, S. S., Duff, S. B., Leon, J., et al. (1999) Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer’s disease. Neurology 52, 1138–1145.

    Article  PubMed  CAS  Google Scholar 

  22. Hardy, J. (1997) Amyloid, the presenilins and Alzheimer’s disease. Trends Neurosci. 20, 154–159.

    Article  PubMed  CAS  Google Scholar 

  23. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer’s Disease. (1997) Consensus recommendations for the postmortem diagnosis of Alzheimer’s disease. Neurobiol. Aging 18, S1 - S2

    Article  Google Scholar 

  24. Small, D. H. (1998) The role of the amyloid protein precursor (APP) in Alzheimer’s disease, does the normal function of APP explain the topography of neurodegeneration? Neurochem. Res. 23, 795–806.

    Article  PubMed  CAS  Google Scholar 

  25. Selkoe, D. J. (1999) Translating cell biology into therapeutic advances in Alzheimer’s disease. Nature 399, A23 - A31

    Article  PubMed  CAS  Google Scholar 

  26. Tilley, L., Morgan, K., and Kalsheker, N. (1998) Genetic risk factors in Alzheimer’s disease. Mol. Pathol. 51, 293–304.

    Article  PubMed  CAS  Google Scholar 

  27. Aisen, P. S. (1997) Inflammation and Alzheimer’s disease, mechanisms and therapeutic strategies. Gerontology 43, 143–149.

    Article  PubMed  CAS  Google Scholar 

  28. Frolich, L. and Riederer, P. (1995) Free radical mechanisms in dementia of Alzheimer type and the potential for antioxidative treatment. Arzneimittel-Forschung 45, 443–446.

    PubMed  CAS  Google Scholar 

  29. Alvarez, A., Toro, R., Caceres, A., and Maccioni, R. B. (1999) Inhibition of tau phosphorylating protein kinase cdk5 prevents beta-amyloid-induced neuronal death. FEBS Lett. 459, 21–426.

    Article  Google Scholar 

  30. Ehrenstein, G., Galdzicki, Z., and Lange, G. D. (1997) The choline-leakage hypothesis for the loss of acetylcholine in Alzheimer’s disease. Biophys. J. 73, 1276–1280.

    Article  PubMed  CAS  Google Scholar 

  31. Kaltschmidt, B., Uherek, M., Wellmann, H., Volk, B., and Kaltschmidt, C. (1999) Inhibition of NF-kappaB potentiates amyloid beta-mediated neuronal apoptosis. Proc. Natl. Acad. Sci. USA 96, 9409–9414.

    Article  PubMed  CAS  Google Scholar 

  32. Hussain, I., Powell, D., Howlett, D. R., Tew, D. G., Meek, T. D., Chapman, C., et al. (1999) Identification of a novel aspartic protease (Asp 2) as betasecretase. Mol. Cell Neurosci. 14, 419–427.

    Article  PubMed  CAS  Google Scholar 

  33. Sinha, S., Anderson, J. P., Barbour, R., Basi, G. S., Caccavello, R., Davis, D., et al. (1999) Purification and cloning of amyloid precursor protein betasecretase from human brain. Nature 402, 537–540.

    Article  PubMed  CAS  Google Scholar 

  34. Vassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., et al. (1999) Beta-secretase cleavage of Alzheimer’s amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286, 735–741.

    Article  PubMed  CAS  Google Scholar 

  35. Yan, R., Bienkowski, M. J., Shuck, M. E., Miao, H., Tory, M. C., Pauley, A. M., et al. (1999) Membrane-anchored aspartyl protease with Alzheimer’s disease beta-secretase activity. Nature 402, 533–537.

    Article  PubMed  CAS  Google Scholar 

  36. Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., et al. (1999) Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400, 173–177.

    Article  PubMed  CAS  Google Scholar 

  37. Durkin, J. T., Murthy, S., Husten, E. J., Trusko, S. P., Savage, M. J., Rotella, D. P., et al. Rank-order of potencies for inhibition of the secretion of abeta40 and abeta42 suggests that both are generated by a single gamma-secretase. J. Biol. Chem. 274, 20499–20504.

    Article  PubMed  CAS  Google Scholar 

  38. Janciauskiene, S., Garcia, D. F., Carlemalm, E., Dahlback, B., and Eriksson, S. (1995) Inhibition of Alzheimer beta-peptide fibril formation by serum amyloid P component. J. Biol. Chem. 270, 26041–26044.

    Article  PubMed  CAS  Google Scholar 

  39. Soto, C. (1999) Plaque busters, strategies to inhibit amyloid formation in Alzheimer’s disease. Mol. Med. Today 5, 343–350.

    Article  PubMed  CAS  Google Scholar 

  40. Zhang, W., Johnson, B. R., and Bjornsson, T. D. (1997) Pharmacologic inhibition of transglutaminase-induced cross—linking of Alzheimer’ s amyloid beta-peptide. Life Sci. 60, 2323–2332.

    Article  PubMed  CAS  Google Scholar 

  41. Howlett, D. R., Perry, A. E., Godfrey, F., Swatton, J. E., Jennings, K. H., Spitzfaden, C., et al. (1999) Inhibition of fibril formation in beta-amyloid peptide by a novel series of benzofurans. Biochem. J. 340, 283–289.

    Article  PubMed  CAS  Google Scholar 

  42. Racchi, M., Solano, D. C., Sironi, M., and Govoni, S. (1999) Activity of alpha-secretase as the common final effector of protein kinase C-dependent and -independent modulation of amyloid precursor protein metabolism. J. Neurochem. 72, 2464–2470.

    Article  PubMed  CAS  Google Scholar 

  43. Kuda, T., Shoji, M., Arai, H., Kawashima, S., and Saido, T. C. (1997) Reduction of plasma glutamyl aminopeptidase activity in sporadic Alzheimer’s disease. Biochem. Biophys. Res. Commun. 231, 526–530.

    Article  PubMed  CAS  Google Scholar 

  44. Price, D. L., Becher, M. W., Wong, P. C., Borchelt, D. R., Lee, M. K., and Sisodia, S. S. (1996) Inherited neurodegenerative diseases and transgenic models. Brain Pathol. 6, 467–480.

    Article  PubMed  CAS  Google Scholar 

  45. Saito, Y., Buciak, J., Yang, J., and Pardridge, W. M. (1995) Vector-mediated delivery of 125I-labeled beta—amyloid peptide A beta 1–40 through the blood-brain barrier and binding to Alzheimer disease amyloid of the A beta 1–40/vector complex. Proc. Natl. Acad. Sci. USA 92, 10227–10231.

    Article  PubMed  CAS  Google Scholar 

  46. Holcomb, L., Gordon, M. N., McGowan, E., Yu, X., Benkovic, S., Jantzen, P., et al. (1998) Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nature Med. 4, 97–100.

    Article  PubMed  CAS  Google Scholar 

  47. Hyman, B. T., Marzloff, K., and Arriagada, P. V. (1993) The lack of accumulation of senile plaques or amyloid burden in Alzheimer’s disease suggests a dynamic balance between amyloid deposition and resolution. J. Neuropathol. Exp. Neurol. 52, 594–600.

    Article  PubMed  CAS  Google Scholar 

  48. Finch, C. E. and Sapolsky, R. M. (1999) The evolution of Alzheimer disease, the reproductive schedule, and apoE isoforms. Neurobiol. Aging 20, 407–428.

    Article  PubMed  CAS  Google Scholar 

  49. Dickson, D. W. (1997) Neuropathological diagnosis of Alzheimer’s disease, a perspective from longitudinal clinicopathological studies. Neurobiol. Aging 18, S21 - S26

    Article  PubMed  CAS  Google Scholar 

  50. Moir, R. D., Lynch, T., Bush, A. I., Whyte, S., Henry, A., Portbury, S., et al. (1998) Relative increase in Alzheimer’ s disease of soluble forms of cerebral Abeta amyloid protein precursor containing the Kunitz protease inhibitory domain. J. Biol. Chem. 273, 5013–5019.

    Article  PubMed  CAS  Google Scholar 

  51. The Ronald and Nancy Reagan Research Institute of the Alzheimer’s Association and the National Institute on Aging Working Group. Consensus report of the Working Group on “Molecular and Biochemical Markers of Alzheimer’s Disease.” (1998) Neurobiol. Aging 19, 109–116.

    Article  Google Scholar 

  52. Sano, M., Ernesto, C., Thomas, R. G., Klauber, M. R., Schafer, K., Grundman, M., et al. (1997) A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer’s disease. The Alzheimer’s Disease Cooperative Study. N. Engl. J. Med. 336, 1216–1222.

    Article  PubMed  CAS  Google Scholar 

  53. Rother, M., Erkinjuntti, T., Roessner, M., Kittner, B., Marcusson, J., and Karlsson, I. (1998) Propentofylline in the treatment of Alzheimer’s disease and vascular dementia, a review of phase III trials. Dement. Geriatr. Cogn. Disord. 9 (Suppl. 1), 36–43.

    Article  PubMed  CAS  Google Scholar 

  54. Zhong, B., Lu, X., and Silverman, R. B. (1998) Syntheses of amino nitrones. Potential intramolecular traps for radical intermediates in monoamine oxidate-catalyzed reactions. Bioorg. Med. Chem. 6, 2405–2419.

    Article  PubMed  CAS  Google Scholar 

  55. Gutzmann, H. and Hadler, D. (1998) Sustained efficacy and safety of idebenone in the treatment of Alzheimer’s disease, update on a 2-year double-blind multicentre study. J. Neural Transm. 54 (Suppl.), 301–310.

    CAS  Google Scholar 

  56. Cesura, A. M., Borroni, E., Gottowik, J., Kuhn, C., Malherbe, P., Martin, J., et al. (1999) Lazabemide for the treatment of Alzheimer’s disease, rationale and therapeutic perspectives. Adv. Neurol. 80, 521–528.

    PubMed  CAS  Google Scholar 

  57. Finberg, J. P., Lamensdorf, I., Commissiong, J. W., and Youdim, M. B. (1996) Pharmacology and neuroprotective properties of rasagiline. J. Neural. Transm. 48 (Suppl.), 95–101.

    CAS  Google Scholar 

  58. McGeer, P. L. and McGeer, E. G. (1999) Inflammation of the brain in Alzheimer’s disease, implications for therapy. J. Leukocyte Biol. 65, 409–415.

    PubMed  CAS  Google Scholar 

  59. Breitner, J. C. (1996) The role of anti-inflammatory drugs in the prevention and treatment of Alzheimer’s disease. Annu. Rev. Med. 47, 401–411.

    Article  PubMed  CAS  Google Scholar 

  60. Scharf, S., Mander, A., Ugoni, A., Vajda, F., and Christophidis, N. (1999) A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer’s disease. Neurology 53, 197–201.

    Article  PubMed  CAS  Google Scholar 

  61. Aisen, P. S., Marin, D., Altstiel, L., Goodwin, C., Baruch, B., Jacobson, R., et al. (1996) A pilot study of prednisone in Alzheimer’s disease. Dementia 7, 201–206.

    PubMed  CAS  Google Scholar 

  62. Tan, J., Town, T., Paris, D., Mori, T., Suo, Z., Crawford, F., et al. (1998) Micro-glial Activation resulting from CD4O-CD4OL interaction after beta-amyloid stimulation. Science 286, 2352–2355.

    Article  Google Scholar 

  63. Mohr, E., Nair, N. P., Sampson, M., Murtha, S., Belanger, G., Pappas, B., et al. (1997) Treatment of Alzheimer’s disease with sabeluzole, functional and structural correlates. Clin. Neuropharmacol. 20, 338–345.

    Article  PubMed  CAS  Google Scholar 

  64. Hoshi, M., Takashima, A., Noguchi, K., Murayama, M., Sato, M., Kondo, S., et al. (1996) Regulation of mitochondrial pyruvate dehydrogenase activity by tau protein kinase I/glycogen synthase kinase 3beta in brain. Proc. Natl. Acad. Sci. USA 93, 2719–2723.

    Article  PubMed  CAS  Google Scholar 

  65. Michel, P., Lambeng, N., and Ruberg, M. (1999) Neuropharmacologic Aspects of Apoptosis, Significance for Neurodegenerative Diseases. Clin. Neuropharmacol. 22, 137–150.

    PubMed  CAS  Google Scholar 

  66. Hefti, F. (1997) Pharmacology of neurotrophic factors. Annu. Rev. Pharmacol. Toxicol. 37, 239–267.

    Article  PubMed  CAS  Google Scholar 

  67. Grundman, M., Corey-Bloom, J., and Thal, L. J. (1998) Perspectives in clinical Alzheimer’s disease research and the development of antidementia drugs. J. Neural Transm. 53 (Suppl.), 255–275.

    Article  CAS  Google Scholar 

  68. Krall, W. J., Sramek, J. J., and Cutler, N. R. (1999) Cholinesterase inhibitors: a therapeutic strategy for Alzheimer disease. Ann. Pharmacother. 33, 441–450.

    Article  PubMed  CAS  Google Scholar 

  69. Avery, E. E., Baker, L. D., and Asthana, S. (1997) Potential role of muscarinic agonists in Alzheimer’s disease. Drugs Aging 11, 450–459.

    Article  PubMed  CAS  Google Scholar 

  70. Sedman, A. J., Bockbrader, H., and Schwarz, R. D. (1995) Preclinical and phase 1 clinical characterization of CI-979/RÚ35926, a novel muscarinic agonist for the treatment of Alzheimer’s disease. Life Sci. 56, 877–882.

    Article  PubMed  CAS  Google Scholar 

  71. Bodick, N. C., Offen, W. W., Levey, A. I., Cutler, N. R., Gauthier, S. G., Satlin, A., et al. (1997) Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch. Neurol. 54, 465–473.

    Article  PubMed  CAS  Google Scholar 

  72. Fisher, A., Heldman, E., Gurwitz, D., Haring, R., Karton, Y., Meshulam, H., et al. (1996) M1 agonists for the treatment of Alzheimer’s disease. Novel properties and clinical update. Ann. NYAcad. Sci. 777, 189–196.

    Article  CAS  Google Scholar 

  73. Lachowicz, J. E., Lowe, D., Duffy, R. A., Ruperto, V., Taylor, L. A., Guzik, H., et al. (1999) SCH 57790: a novel M2 receptor selective antagonist. Life Sci. 64, 535–539.

    Article  PubMed  CAS  Google Scholar 

  74. Muller, D., Wiegmann, H., Langer, U., Moltzen-Lenz, S., and Nitsch, R. M. Lu (1998) 25–109, a combined ml agonist and m2 antagonist, modulates regulated processing of the amyloid precursor protein of Alzheimer’s disease. J. Neural. Transm. 105, 1029–1043.

    Article  PubMed  CAS  Google Scholar 

  75. Potter, A., Corwin, J., Lang, J., Piasecki, M., Lenox, R., and Newhouse, P. A. (1999) Acute effects of the selective cholinergic channel activator (nicotinic agonist) ABT-418 in Alzheimer’s disease. Psychopharmacology (Berl.) 142, 334–342.

    Article  CAS  Google Scholar 

  76. Vernier, J. M., El-Abdellaoui, H., Holsenback, H., Cosford, N. D., Bleicher, L., Barker, G., et al. (1999) 4-[[2-(1-Methyl-2-pyrrolidinyl)ethyl]thio]phenol hydrochloride (SIB-1553A), a novel cognitive enhancer with selectivity for neuronal nicotinic acetylcholine receptors. J. Med. Chem. 42, 1684–1686.

    Article  PubMed  CAS  Google Scholar 

  77. Arendash, G. W., Sengstock, G. J., Sanberg, P. R., and Kem, W. R. (1995) Improved learning and memory in aged rats with chronic administration of the nicotinic receptor agonist GTS-21. Brain Res. 674, 252–259.

    Article  PubMed  CAS  Google Scholar 

  78. Murai, S., Saito, H., Abe, E., Masuda, Y., Odashima, J., and Itoh, T. (1994) MKC-231, a choline uptake enhancer, ameliorates working memory deficits and decreased hippocampal acetylcholine induced by ethylcholine aziridinium ion in mice.. J. Neural. Transm. Gen. Sect. 98, 1–13.

    Article  PubMed  CAS  Google Scholar 

  79. Mellow, A. M., Aronson, S. M., Giordani, B., and Berent, S. (1993) A peptide enhancement strategy in Alzheimer’s disease, pilot study with TRH—physostigmine infusions. Biol. Psychiatry 34, 271–273.

    Article  PubMed  CAS  Google Scholar 

  80. Horita, A., Carino, M. A., Zabawska, J., and Lai, H. (1989) TRH analog MK-771 reverses neurochemical and learning deficits in medial septallesioned rats. Peptides 10, 121–124.

    Article  PubMed  CAS  Google Scholar 

  81. Behan, D. P., Heim-ichs, S. C., Troncoso, J. C., Liu, X. J., Kawas, C. H., Ling, N., et al. (1995) Displacement of corticotropin releasing factor from its binding protein as a possible treatment for Alzheimer’s disease. Nature 378, 284–287.

    Article  PubMed  CAS  Google Scholar 

  82. Toide, K., Shinoda, M., and Miyazaki, A. (1998) A novel prolyl endopeptidase inhibitor, JTP-4819—its behavioral and neurochemical properties for the treatment of Alzheimer’s disease. Rev. Neurosci. 9, 17–29.

    PubMed  CAS  Google Scholar 

  83. Hampson, R. E., Rogers, G., Lynch, G., and Deadwyler, S. A. (1998) Facilitative effects of the ampakine CX516 on short-term memory in rats: enhancement of delayed-nonmatch-to-sample performance. J. Neurosci. 18, 2740–2747.

    PubMed  CAS  Google Scholar 

  84. Fakouhi, T. D., Jhee, S. S., Sramek, J. J., Benes, C., Schwartz, P., Hantsburger, G., et al. (1995) Evaluation of cycloserine in the treatment of Alzheimer’s disease. J. Geriatr. Psychiatry Neurol. 8, 226–230.

    PubMed  CAS  Google Scholar 

  85. Craft, S. (1999) Enhancement of memory in Alzheimer disease with insulin and somatostatin, but not glucose. Arch. Gen. Psychiatry. 56, 1135–1140.

    Article  PubMed  CAS  Google Scholar 

  86. Abe, K., Takeyama, C., and Yoshimura, K. (1998) Effects of S-8510, a novel benzodiazepine receptor partial inverse agonist, on basal forebrain lesioninginduced dysfunction in rats. Eur. J. Pharmacol. 347, 145–152.

    Article  PubMed  CAS  Google Scholar 

  87. Ott, B. R., Thompson, J. A., and Whelihan, W. M. (1996) Cognitive effects of flumazenil in patients with Alzheimer’s disease. J. Clin. Psychopharmacol. 16, 400–402.

    Article  PubMed  CAS  Google Scholar 

  88. van Duijn, C. M. (1999) Hormone replacement therapy and Alzheimer’s disease. Maturitas 31, 201–205.

    Article  PubMed  Google Scholar 

  89. Treves, T. A. and Korczyn, A. D. (1999) Denbufylline in dementia, A double-blind controlled study. Dement. Geriatr. Cogn. Disord. 10, 505–510.

    Article  PubMed  CAS  Google Scholar 

  90. Parnetti, L., Ambrosoli, L., Abate, G., Azzini, C., Balestreri, R., Bartorelli, L., et al. (1995) Posatirelin for the treatment of late-onset Alzheimer’s disease, a double–blind multicentre study vs citicoline and ascorbic acid. Acta Neurolog. Scand. 92, 135–140.

    Article  CAS  Google Scholar 

  91. Markesbery, W. R. (1997) Oxidative stress hypothesis in Alzheimer’s disease. Free Radical Biol. Med. 23, 134–147.

    Article  CAS  Google Scholar 

  92. Mimori, Y., Katsuoka, H., and Nakamura, S. (1996) Thiamine therapy in Alzheimer’s disease. Metab. Brain Dis. 11, 89–94.

    Article  PubMed  CAS  Google Scholar 

  93. Thal, L. J., Carta, A., Clarke, W. R., Ferris, S. H., Friedland, R. P., Petersen, R. C., et al. A 1-year multicenter placebo-controlled study of acetyl-L-carnitine in patients with Alzheimer’s disease. Neurology 47, 705–711.

    Google Scholar 

  94. Fleischhacker, W. W., Buchgeher, A., and Schubert, H. (1986) Memantine in the treatment of senile dementia of the Alzheimer type. Pro g. Neuropsychopharmacol. Biol. Psychiatry 10, 87–93.

    Article  CAS  Google Scholar 

  95. Goedert, M. (1996) Tau protein and the neurofibrillary pathology of Alzheimer’s disease. Ann. NYAcad. Sci. 777, 121–131.

    Article  CAS  Google Scholar 

  96. Sperfeld, A. D., Collatz, M. B., Baier, H., Palmbach, M., Storch, A., Schwarz, J., et al. (1999) FTDP-17, an early-onset phenotype with parkinsonism and epileptic seizures caused by a novel mutation. Ann. Neurol. 46, 708–715.

    Article  PubMed  CAS  Google Scholar 

  97. Imahori, K., Hoshi, M., Ishiguro, K., Sato, K., Takahashi, M., Shiurba, R., et al. (1998) Possible role of tau protein kinases in pathogenesis of Alzheimer’s disease. Neurobiol. Aging 19, S93–S98

    Article  PubMed  CAS  Google Scholar 

  98. Trojanowski, J. Q. and Lee, V. M. (1995) Phosphorylation of paired helical filament tau in Alzheimer’s disease neurofibrillary lesions, focusing on phosphatases. FASEB J. 9, 1570–1576.

    PubMed  CAS  Google Scholar 

  99. Snowdon, D. A., Greiner, L. H., Mortimer, J. A., Riley, K. P., Greiner, P. A., and Markesbery, W. R. (1997) Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA 277, 813–817.

    Article  PubMed  CAS  Google Scholar 

  100. Sparks, D. L. (1997) Coronary artery disease, hypertension, ApoE, and cholesterol, a link to Alzheimer’s disease? Ann. NYAcad. Sci. 826, 128–146.

    Article  CAS  Google Scholar 

  101. Forette, F., Seux, M. L., Staessen, J. A., Thijs, L., Birkenhager, W. H., Babarskiene, M. R., et al. (1998) Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 352, 1347–1351.

    Article  PubMed  CAS  Google Scholar 

  102. Tedesco, M. A., Ratti, G., Mennella, S., Manzo, G., Grieco, M., Rainone, A. C., et al. (1999) Comparison of losartan and hydrochlorothiazide on cognitive function and quality of life in hypertensive patients. Am. J. Hypertens. 12, 1130–1134.

    Article  PubMed  CAS  Google Scholar 

  103. Alexander, G. E., Furey, M. L., Grady, C. L., Pietrini, P., Brady, D. R., Mentis, M. J., et al. (1997) Association of premorbid intellectual function with cerebral metabolism in Alzheimer’s disease, implications for the cognitive reserve hypothesis. Am. J. Psychiatry 154, 165–172.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Michael Gold
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kevin M. Felsenstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Perry Molinoff
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Springer Science+Business Media New York

About this chapter

Cite this chapter

Gold, M., Felsenstein, K.M., Molinoff, P. (2001). Treatment Approaches for Alzheimer’s Disease. In: Molecular Mechanisms of Neurodegenerative Diseases. Contemporary Clinical Neuroscience. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-006-3_6

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-006-3_6

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61737-197-4

  • Online ISBN: 978-1-59259-006-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation